Common use of Restricted Use Clause in Contracts

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/Botulinum Toxin Type A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (HeparescDysport®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing ICB Muscle spasticity in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As neuromuscular conditions - cerebral palsy - as per National Demand Management Plan - NHSE locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Botulinum Toxin Type A (FlebogammaBotox®, Dysport®) (Flebogamma®) NHSE As ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Botulinum Toxin Type A and B (Gammanorm®) (GammanormBotox®) NHSE As per National Demand Management Plan - NHSE policy Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Botulinum Toxin Type A and B (Gammaplex®) (GammaplexBotox®) NHSE As per National Demand Management Plan - NHSE policy Focal spasticity in children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Brentuximab vedotin (Gamunex®) (GamunexAdcetris®) NHSE As CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per National Demand Management Plan NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Adcetris®) NHSE policy Treating CD30-positive cutaneous T- cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 Hospital Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 Hospital Brexucabtagene autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 Hospital Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 Hospital Brigatinib Alunbrig® NHSE ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 Hospital Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Brimonidine tartrate gel (Mirvaso®) ICB Treatment of facial erythema (rosacea) Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Brincidofovir ((CMX001)) NHSE CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Brivaracetam Briviact ICB epilepsy as alternative to levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Brodalumab (Kyntheum®) ICB Moderate to severe plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA511 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA672 – February 2021 BLUE Brolucizumab Beovu® ICB diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA820 – August 2022 BLACK Bromocriptine () ICB Pharmacological neuroprotective therapy in ▇▇▇▇▇▇▇▇▇'▇ disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NICE NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk®) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk®) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 Hospital Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 Hospital Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. BLUE Buprenorphine Long- Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 Hospital Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Butyrophenones (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Cabazitaxel (Jevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 Hospital Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital Cabotegravir Vocabria® NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Hizentraassume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Cabozantinib (HizentraCometriq®) NHSE As For treating medullary thyroid cancer - as per National Demand Management Plan NICE TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Hospital Cabozantinib (Cabometyx®) NHSE policy Plan Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 Hospital Cabozantinib Cabometyx® NHSE policy previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care TA928 – November 2023 Hospital Cabozantinib ▼ (Cabometyx® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)- targeted therapy - as per NICE TA 463 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA463 - Aug 17 Hospital Calcifidiol NHSE Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.. BLACK Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Double Red Calcium channel blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Bevacizumab (LMWH) (VariousAvastin®) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Bexarotene (VariousTargretin®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Bezafibrate (Bezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Prevention of recurrent clostridium difficile infection (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA601 - Sep 19 Hospital Bictecravir (in combination with emtricitabine and tenofivir alafenamide) Biktarvy ®) NHSE HIV infection / post exposure prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Bimagrumab (PEP(BYM338)) NHSE Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (Mektovi®) NHSE (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Birch bark extract n/a NHSE epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST28 – September 2023 Hospital Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - as per NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA230 - Jul 11 Hospital Blinatumomab (Blincyto®) NHSE Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 Hospital Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy Hospital Boceprevir (VariousVictrelis®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB NHSE Treatment of urinary incontinence genotype 1 chronic hepatitis C - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema TA 253 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 TA253 - Apr 12 Hospital Human heterologous liver cells Bortezomib (HHLivC) (HeparescVelcade®) NHSE Urea cycle disorders Multiple myeloma (first line) - as per NICE 228 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan TA228 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Jul 11

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Gevokizumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) Gilteritinib Xospata® NHSE HIV infection / post exposure prophylaxis (PEP) relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance TA642 – August 2020 Hospital Human alpha-1 proteinase inhibitor Givosiran Givlaari NHSE Emphysema Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. HST16 - Nov 2021 BLACK Human alpha1- proteinase inhibitor N/A emphysema Glasdegib () NHSE with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA965 TA646 – March 2024 September 2020 Hospital Human heterologous liver cells Glatiramer (HHLivC) (HeparescCopaxone®) NHSE Urea cycle disorders Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Hospital Glecaprevir-pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Glofitamab Columvi® NHSE relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Aragam®) (Aragam®Voraxase) NHSE As Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin BLACK Glucocorticoids (Flebogamma®inc hydrocortisone, prednisolone) (Flebogamma®Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Gluten-free foods (Various) ICB Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glycerol phenylbutyrate (Ravicti® 1.1 g/ml oral liquid) NHSE As per National Demand Management Plan Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin GlycoPEGylated Factor IX (Gammagard®) (GammagardRebinyn®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (Humira® / Biosimilar) NHSE Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 Hospital Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil- based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 Hospital Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 Hospital Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 Hospital Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Aflibercept (LMWH) (VariousEylea®) ICB DVT Treatment of Wet Age-related Macular Degeneration (if suspected out AMD) as part of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber a treat and extend regimen in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain line with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Aflibercept (Variousswitched to Ranibizumab (Lucentis®) (Eylea®) ICB Switching between products in the treatment of Wet Age-related Macular Degeneration (AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG82 - Jan 18 Hospital Agalsidase alfa and beta (Replagal® (alpha) / Fabrazyme® (beta)) NHSE HIV infection / post exposure prophylaxis Fabry disease (PEPα-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy BLACK Agomelatine (VariousValdoxan®) ICB Various 4th line use in depression where other treatments have failed or not been tolerated (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRTterminated appraisal) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 TA231 - Nov 15 NF HRT implants Sep 11 Hospital Albumin bound paclitaxel Abraxane ® NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA476 - Sep 17 Hospital Albutrenpenonacog alfa (VariousIdelvion) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Haemophilia B - as per NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissionedDM Albutropin NHSE Adult onset growth hormone deficiency . No NHS prescribing in primary or secondary care TA965 – March 2024 Discontinued Medicines NICE has not issued any guidance. Hospital Human heterologous liver cells Aldesleukin (HHLivC) (Heparesc®Proleukin) NHSE Urea cycle disorders Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Alectinib (Aragam®) (AragamAlecensa®) NHSE As Untreated ALK-positive advanced non- small-cell lung cancer - as per National Demand Management Plan NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alectinib ▼ (Alecensa® ▼) NHSE Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 Hospital Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab (MabCampath®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 - May 14 Double Red Alendronate / Vitamin D3 combination (Fosavance®) ICB Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency Not recommended for routine use NICE has not issued any guidance. GREEN Alendronic acid (sodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Alglucosidase alfa (Myozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha-glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Alipogene tiparvovec (Glybera®) NHSE (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Alirocumab ▼ (Flebogamma®Praluent® ▼) (Flebogamma®) NHSE As ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per National Demand Management Plan NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL- 025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. Hospital Human normal immunoglobulin Alitretinoin (GammagardToctino®) ICB Treatment of severe chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone- receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (Gammagardterminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 Hospital Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 Hospital Alpha-mannosidase - recombinant human (Lamazym®) NHSE As Alpha Mannosidase deficiency - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin GREEN Alprostadil cream (GammanormVitaros®) ICB Erectile dysfunction (Gammanormas per SLS conditions only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA264 - Sep 12 Double Red Amantadine Hydrochloride (Lysovir®) ICB Treatment and prophylaxis of influenza Not recommended for routine use TA168 - Feb 09 Hospital Ambrisentan (Volibris® ▼) NHSE As Pulmonary Arterial Hypertension - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Amifampridine (phosphate) ▼ (Firdapse® ▼) NHSE Treatment of myasthenias - ▇▇▇▇▇▇▇- ▇▇▇▇▇ syndrome - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Amikacin - liposomal for inhalation (Gammaplex®) (GammaplexArikace®) NHSE As per National Demand Management Plan Gram-negative bacterial infection in Cystic Fibrosis . Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Amikacin (for inhalation) (Amikin®) NHSE Gram-negative bacterial infection in Cystic Fibrosis Not recommended for routine use NICE has not issued any guidance. BLACK Aminobenzoic acid (capsules and powder) (Potaba®) ICB Peyronie's disease, Scleroderma Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. AMB 2 Amiodarone (Cordarone X®) ICB Supraventricular and ventricular arrhythmias Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly CG180 - Jun 14 BLACK Amivantamab n/a NHSE policy EGFR exon 20 insertion mutation- positive advanced non-small-cell lung cancer after platinum-based chemotherapy Not commissioned. No NHS prescribing in primary or secondary care TA850 – December 2022 BLACK Amorolfine (Loceryl and other equivalent preparations) ICB Fungal nail infections Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Amphotericin B, itraconazole & voriconazole (Various) NHSE Chronic Pulmonary Aspergillosis (CPA) - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Anabasum NHSE Scleroderma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB Anagrelide ▼ (Xagrid® ▼ / Agrelin® / Agrylin®) ICB Thrombocythaemia Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Anakinra Kineret® NHSE Still’s disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA685 – March 2021 Hospital Anakinra (Kineret®) NHSE Cryopyrin-associated periodic syndrome (CAPS) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Anakinra (Gamunex®) (GamunexKineret®) NHSE As per National Demand Management Plan - NHSE policy Adult onset Still's disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Anakinra (Hizentra) (HizentraKineret®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.NG100 - Oct 2020 Hospital Anakinra (Kineret®) NHSE Juvenile Idiopathic Arthritis (JIA) Res

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Arimoclomol NHSE ▇▇▇▇▇▇▇ Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight ADVICE Aripiprazole (LMWH) (currently under review) (VariousAbilify®) ICB For patients requiring long term anticoagulation Moderate to severe manic episodes in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults adolescents with bipolar I disorder - as per RMOC guidance NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Feb 2019Abilify®) Not recommended for routine use ICB Schizophrenia and bipolar mood disorder - as per NICE has not issued CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil unlicensed thyroid products (Armour Thyroid) ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Any indication Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various, including St John's Wort) (Various) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per East of England PAC policy Not commissioned. No NHS prescribing in local protocol Formulary - Specialist advice required from primary or secondary care NICE has not issued any guidance. clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital HIV vaccine Arsenic trioxide (HIV vaccineTrisenox®) NHSE HIV infection prophylaxis Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital Xerotin Oral spray or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Variousother cost- effective product) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued Xerostomia from any guidance. BLACK Hormone Replacement Therapy (HRT) cause where simple measures alone have been ineffective Formulary - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing Drugs that can be initiated by Prescriber in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary Primary Care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor Asciminib Scemblix® NHSE Emphysema chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells Atacicept (HHLivC) (Heparesc®) NHSE Urea cycle disorders Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Ataluren ▼ (Aragam®Translarna® ▼) NHSE Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST22 - Feb 2023 Hospital Atazanavir (AragamReyataz®) NHSE As HIV infection in combination with other antiretroviral drugs - as per National Demand Management Plan - NHSE policy BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Atazanavir and Cobicistat (Flebogamma®) (FlebogammaEvotaz®) NHSE As HIV infection in combination with other antiretroviral drugs - as per National Demand Management Plan BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Atezolizumab (Gammagard®) (GammagardTecentriq®) NHSE As Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per National Demand Management Plan - NHSE policy NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan TA520 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.May 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA47 - Sep 02 RED Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 RED Eptotermin alfa () NHSE Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) Erectile dysfunction drugs (Various) ICB DVT (if suspected out Erectile dysfunction - limited categories of hours - first dose only) patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) RED Erectile dysfunction drugs (Various) ICB Unstable angina/coronary artery disease/NSTEMI Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin BLUE Erenumab Aimovig® ICB Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA682 – March 2021 ADVICE Ergocalciferol / Vitamin D Injections ICB Vitamin D deficiency Formulary - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated Specialist advice required from primary or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Double Red Heparinised saline RED Eribulin (Saline Halaven®) NHSE Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (heparinised)which may include an anthracycline or a taxane, and capecitabine) ICB Central venous catheter lock in adults - as per RMOC guidance NICE TA 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 RED Eribulin (Feb 2019Halaven®) Not recommended NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for routine use Prescriber NICE has not issued any guidance. Guidance BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE TA 515 Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort TA515 - Mar 18 BLACK Erlotinib (Various, including St John's WortTarceva®) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per East of NICE TA 227 and NHS England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine TA227 - Jun 11 RED Erlotinib (HIV vaccineTarceva®) NHSE HIV infection prophylaxis First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 RED Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion- dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments RED Erythropoietin / Epoetin (VariousEprex®, NeoRecormo n® and others) NHSE HIV infection / post exposure prophylaxis (PEP) Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy CG114 - Nov 11 Double Red Erythropoietin / Epoetin (VariousEprex®, NeoRecormo n® and others) ICB Various (Anaemia in renal failure pre- dialysis. Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. recommended for routine use NG8 - Jun 15 BLACK Hormone Replacement Therapy (HRT) - systemic (Various) Esketamine Spravato® ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants TA854 – December 2022 BLACK Esketamine Spravato® ICB major depressive disorder in adults at imminent risk of suicide (Variousterminated appraisal) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 TA899 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist serviceJune 2023 BLACK Eslicarbazepin e Zebinix® ICB Epilepsy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist serviceBLACK Eslicarbazepin e Zebinix® ICB Trigeminal neuralgia Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin ADVICE Esomeprazole (Flebogamma®Generic) (Flebogamma®) NHSE As per National Demand Management Plan Restricted ICB Limited use – Prescribing where other PPI options have been ineffective; ▇▇▇▇▇▇▇'▇ oesophagus Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care initiation NICE has not issued any guidance. Hospital Human normal immunoglobulin Double Red Esomeprazole (GammagardNexium®, Emozul®, Generic available) (Gammagard®) NHSE As per National Demand Management Plan ICB First line PPI option for licensed indications - NHSE policy Restricted Not recommended for routine use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A (Dysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Botulinum Toxin Type A and B (Botox®) NHSE Intravesical use in spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Botulinum Toxin Type A and B (LMWHBotox®) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber NHSE Focal spasticity in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI children Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight Hospital Brentuximab vedotin (LMWHAdcetris®) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per RMOC guidance NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 Hospital Brentuximab vedotin (Feb 2019Adcetris®) Not recommended for routine NHSE Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use NICE has not issued any guidance– Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 Hospital Brentuximab vedotin (Adcetris®) NHSE in combination for untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Hospital Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 Hospital Brexucabtagene autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 Hospital Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non- small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Brigatinib Alunbrig® NHSE ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 Hospital Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort BLACK Brimonidine tartrate gel (Various, including St John's WortMirvaso®) ICB All uses Treatment of facial erythema (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aqrosacea) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine Brincidofovir (HIV vaccine(CMX001)) NHSE HIV CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Brivaracetam Briviact ICB epilepsy as alternative to levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Brodalumab (Kyntheum®) ICB Moderate to severe plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA511 - Mar 18 Hospital Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA672 – February 2021 BLUE Brolucizumab Beovu® ICB diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA820 – August 2022 BLACK Bromocriptine () ICB Pharmacological neuroprotective therapy in ▇▇▇▇▇▇▇▇▇'▇ disease (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Bromocriptine mesilate (Parlodel®) ICB First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NICE NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk®) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk®) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Budesonide (oral viscous slurry) Pulmicort respules ICB eosinophilic oesophagitis in adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 Hospital Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 Hospital Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15- 30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLUE Buprenorphine Long- Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 Hospital Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 Hospital Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Butyrophenones (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Hospital C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments BLACK Cabazitaxel (VariousJevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 Hospital Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Cabotegravir Vocabria® NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy Hospital Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 Hospital Cabozantinib (VariousCometriq®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence NHSE For treating medullary thyroid cancer - as per NICE CG 171 TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Hospital Cabozantinib (Cabometyx®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE Do Not Do (Not a licensed indication)TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 Hospital Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care CG171 TA928 – November 2023 Hospital Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 Hospital Cabozantinib ▼ (Cabometyx® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)- targeted therapy - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary as per NICE has not issued any guidanceTA 463 Restricted use – Prescribing to remain with the hospital or specialist service. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance No prescribing in primary care TA463 - Aug 17 Hospital Human alpha-1 proteinase inhibitor Calcifidiol NHSE Emphysema Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Double Red Calcium channel blockers - various (Aragam®Various) (Aragam®) NHSE As ICB Treatment of cor pulmonale - as per National Demand Management Plan NICE CG 101 - NHSE policy Restricted NICE Do Not Do Not recommended for routine use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan CG101 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Jul 10

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ADVICE Chloral hydrate 500mg/5ml oral solution n/a ICB DVT (if suspected out off-label use in treatment of hours - first dose only) dystonia Formulary - Drugs that can be initiated by Prescriber in Primary Care Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight RED Chlorambucil (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - SaizenLeukeran®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Chlorhexidine Mouthwash (Various) ICB prophylaxis against infective endocarditis to people at risk of infective endocarditis undergoing dental procedures - as per NICE CG 64 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA965 CG64 - Jul 16 RED Chlormethine gel Ledaga® NHSE mycosis fungoides-type cutaneous T-cell lymphoma Restricted use – March 2024 Hospital Human heterologous liver cells Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA720 – August 2021 DM Chlorpropamid e (HHLivC) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (Heparescassume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Cholesterol and Simvastatin cream n/a ICB disseminated superficial actinic porokeratosis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. RED Cholic acid (Orphacol®, Kolbam®) NHSE Urea cycle disorders Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin BLACK Chondroitin (AragamVarious) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 ADVICE Ciclosporin (Ikervis®) ICB Severe keratitis in adult patients with dry eye disease that has not improved despite treatment with tear substitutes (AragamConsultant recommendation only) - as per NICE TA 369 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA369 - Dec 15 SCA Ciclosporin (Various brands - to be specified by prescribers) ICB Rheumatic and dermatological diseases. Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NG100 - Jul 18 RED Cidofovir (Vistide®) NHSE As per National Demand Management Plan - NHSE policy Cytomegalovirus (CMV) infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin BLACK Cilostazol (FlebogammaPletal®) (Flebogamma®) NHSE As ICB Treatment of intermittent claudication in people with peripheral arterial disease - as per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist serviceNICE TA 223 Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) TA223 - May 11 BLACK Ciltacabtagene autoleucel n/a NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital relapsed or specialist servicerefractory multiple myeloma Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use TA889 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.May 2023

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Bevacizumab (Avastin®) ICB Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Bexarotene (Targretin®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Bezafibrate (Bezalip; Fibrazate) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Zinplava®) ICB Prevention of recurrent clostridium difficile infection (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA601 - Sep 19 RED Bictecravir (in combination with emtricitabine and tenofivir alafenamide) Biktarvy ®) NHSE HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Bimagrumab ((BYM338)) NHSE Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin RED Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 RED Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 RED Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 RED Binimetinib (Mektovi®) NHSE (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - Low Molecular Weight as per NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (LMWHBioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS prescribing in primary or secondary care NG23 - Nov 13 RED Biotin (vitamin H) (VariousQizenday®, Cerenday®, MD1003) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform RED Birch bark extract n/a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST28 – September 2023 RED Bivalirudin (Angiox®) ICB Treatment of ST-segment-elevation myocardial infarction - as per NICE has not issued any guidanceTA 230 Restricted use – Prescribing to remain with the hospital or specialist service. Hospital HIV/AIDS treatments No prescribing in primary care TA230 - Jul 11 Traffic Light Classification Drug Name Brand Name Commissioner Indication (Variousassume licenced unless stated) Instructions for Prescriber NICE Guidance RED Blinatumomab (Blincyto®) NHSE HIV infection / post exposure prophylaxis Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (PEPterminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 RED Blinatumomab ▼ (Blincyto® ▼) NHSE Philadelphia-chromosome-negative relapsed or refractory precursor B- cell acute lymphoblastic leukaemia in adults - as per NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA450 - Jun 17 RED Blisibimod () NHSE Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy RED Boceprevir (VariousVictrelis®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB NHSE Treatment of urinary incontinence genotype 1 chronic hepatitis C - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema TA 253 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells TA253 - Apr 12 RED Bortezomib (HHLivC) (HeparescVelcade®) NHSE Urea cycle disorders Multiple myeloma (first line) - as per NICE 228 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin TA228 - Jul 11 RED Bortezomib (Aragam®) (AragamVelcade®) NHSE As Induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation - as per National Demand Management Plan - NHSE policy NICE TA 311 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin TA311 - Apr 14 RED Bortezomib (Flebogamma®) (FlebogammaVelcade®) NHSE As Previously untreated mantle cell lymphoma in adults for whom haematopoietic stem cell transplantation is unsuitable as per National Demand Management Plan NICE TA 370 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan TA370 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Dec 15

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Gevokizumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) Gilteritinib Xospata® NHSE HIV infection / post exposure prophylaxis (PEP) relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance TA642 – August 2020 Hospital Human alpha-1 proteinase inhibitor Givosiran Givlaari NHSE Emphysema Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. HST16 - Nov 2021 BLACK Human alpha1- proteinase inhibitor N/A emphysema Glasdegib () NHSE with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA965 TA646 – March 2024 September 2020 Hospital Human heterologous liver cells Glatiramer (HHLivC) (HeparescCopaxone®) NHSE Urea cycle disorders Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Glecaprevir- pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Glofitamab Columvi® NHSE relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA927 – October 2023 Hospital Glucarpidase (Aragam®) (Aragam®Voraxase) NHSE As Urgent treatment of methotrexate- induced renal dysfunction in patients receiving high-dose MTX chemotherapy - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin BLACK Glucocorticoids (Flebogamma®inc hydrocortisone, prednisolone) (Flebogamma®Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Gluten-free foods (Various) ICB Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glycerol phenylbutyrate (Ravicti® 1.1 g/ml oral liquid) NHSE As per National Demand Management Plan Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin GlycoPEGylated Factor IX (Gammagard®) (GammagardRebinyn®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Arimoclomol NHSE ▇▇▇▇▇▇▇ Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Abilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (Armour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Aromatase inhibitors (Various) (Various) ICB Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost-effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. Hospital Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Ataluren ▼ (Translarna® ▼) NHSE Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST22 - Feb 2023 Hospital Atazanavir (Reyataz®) NHSE HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Atazanavir and Cobicistat (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - SaizenEvotaz®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis in combination with other antiretroviral drugs - as per BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Atezolizumab (VariousTecentriq®) NHSE HIV infection / post exposure prophylaxis (PEP) Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy TA520 - May 18 Hospital Atezolizumab (VariousTecentriq®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence NHSE Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema TA 525 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 TA525 - Jun 18 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) Atezolizumab Tecentriq® NHSE Urea cycle disorders monotherapy for untreated advanced non-small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA705 – June 2021 Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) Atezolizumab Tecentriq® NHSE As per National Demand Management Plan - NHSE policy untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA739 – October 2021 BLACK Atezolizumab TECENTRIQ® NHSE with carboplatin and nab-paclitaxel for untreated advanced non-squamous non- small-cell lung cancer as per TA618 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA618 - Jan 20 Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) Atezolizumab Tecentriq® NHSE As per National Demand Management Plan adjuvant treatment of resected non-small cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA823 – October 2022 Hospital Human normal immunoglobulin Atezolizumab▼ (Gammagard®) (Gammagard®Tecentriq® ▼) NHSE As per National Demand Management Plan - NHSE policy with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA638 - July 2020 Hospital Human normal immunoglobulin Atezolizumab▼ (Gammanorm®) (Gammanorm®Tecentriq® ▼) NHSE As per National Demand Management Plan - NHSE policy with nab-paclitaxel for untreated PD-L1- positive, locally advanced or metastatic, triple-negative breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA639 - July 2020 Hospital Human normal immunoglobulin Atezolizumab▼ (Gammaplex®) (Gammaplex®Tecentriq® ▼) NHSE As per National Demand Management Plan - NHSE policy with bevacizumab for treating advanced or unresectable hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use TA666 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.December 2020

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) Factor XIII NHSE HIV infection prophylaxis Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments FactorR VIII Inhibitor Bypassing Factor (VariousFEIBA) NHSE HIV infection / post exposure prophylaxis (PEP) Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy BLACK Fampridine (VariousFampyra®) ICB Various NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRTEDSS 4-7) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Nov 15 NF HRT implants Oct 06 Hospital Fibrin sealants (VariousFibrin sealants) NHSE Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibrinogen, dried (Human) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Hormone replacement therapy Non-formulary Treatment of mild to moderate C. difficile infection (CDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 TA676 – March 2024 February 2021 Hospital Human heterologous liver cells Filgotinib (HHLivC) (Heparesc®) NHSE Urea cycle disorders Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim (Aragam®) (Aragam®) NHSE As ▇▇▇▇▇ Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Double Red Filibuvir (Flebogamma®) (Flebogamma®) NHSE As Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per National Demand Management Plan NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan TA254 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Apr 12

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) Factor XIII NHSE HIV infection prophylaxis Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments FactorR VIII Inhibitor Bypassing Factor (VariousFEIBA) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA965 NICE has not issued any guidance. BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – March 2024 September 2017 Hospital Human heterologous liver cells Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (HHLivCAdenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (HeparescAbstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. GREEN Fesoterodine M-R (Toviaz®) ICB Increased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care CG171 - Oct 06 Hospital Fibrin sealants (Fibrin sealants) NHSE Urea cycle disorders Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Fibrinogen, dried (AragamHuman) () NHSE Treatment of haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Fibroblast growth factor 1 (FGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (AragamCDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE As Paediatric indications (where adult TA available) - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim () NHSE ▇▇▇▇▇ Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Filgrastim (Various ▼) NHSE Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Double Red Filibuvir (Flebogamma®) (Flebogamma®) NHSE As Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLUE Finerenone Kerendia® ICB chronic kidney disease in type 2 diabetes NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA877- March 2023 Hospital Fingolimod ▼ (Gilenya® ▼) NHSE Highly active relapsing remitting multiple sclerosis as per National Demand Management Plan NICE TA 254 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan TA254 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Apr 12

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor X (Coagadex) NHSE Hereditary factor X deficiency Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Factor XIII NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital FactorR VIII Inhibitor Bypassing Factor (FEIBA) NHSE Specialist indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Fampridine (Fampyra®) NHSE Improvement of walking in adults with Multiple Sclerosis with walking disability (EDSS 4-7) - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Farco-fill Protect ICB Indwelling urinary catheterisation Not commissioned. No NHS prescribing in primary or secondary care MIB 121 – September 2017 Hospital Faricimab Vabysmo® ICB diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA799 – June 2022 Hospital Faricimab Vabysmo® ICB wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA800 – June 2022 GREEN Febuxostat (Adenuric®) ICB Management of chronic hyperuricaemia in patients with gout who are intolerant of allopurinol - as per NICE TA 164 Formulary - Drugs that can be initiated by Prescriber in Primary Care TA164 - Dec 08 Hospital Fedratinib Inrebic® NHSE disease-related splenomegaly or symptoms in myelofibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA756 – December 2021 Hospital Fenfluramine Fintepla® NHSE seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA808 – July 2022 Double Red Fenofibrate (Lipantil®; Supralip®; Cholib®) ICB Prevention of CVD - as per NICE CG 181 "Do Not Do" (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Fentanyl I-R - buccal tabs, loz, nasal sprays (Effentora®, Actiq®, Instanyl®, PecFent®) ICB (Acute) breakthrough pain in cancer Not recommended for routine use CG140 - July 12 Hospital Fentanyl I-R sublingual tabs (Abstral®) (Abstral®) ICB 3rd line option for (Acute) breakthrough pain in cancer as part of an agreed pathway of care Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults (see separate Red entry regarding use in IBD) Not recommended for routine use NICE has not issued any guidance. Hospital Ferric maltol (Feraccru®) (Feraccru®) ICB Treatment of iron-deficiency anaemia in adults with Inflammatory Bowel Disease that are intolerant of at least 2 other oral iron products Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Fesoterodine M-R (LMWH) (VariousToviaz®) ICB DVT (if suspected out of hours - first dose onlyIncreased urinary frequency and/or urgency and/or urgency incontinence) in Overactive Bladder Syndrome Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 CG171 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq 06 Hospital Fibrin sealants (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccineFibrin sealants) NHSE HIV infection prophylaxis Haemostatic / tissue glue Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Fibrinogen, dried (VariousHuman) () NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence haemorrhage in congenital hypofibrinogenaemia or afibrinogenaemia - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders BCSH guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Fibroblast growth factor 1 (AragamFGF1) gene therapy () NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Fidaxomicin (Dificlir®) ICB Treatment of mild to moderate C. difficile infection (AragamCDI) in patients who have had two previous episodes in the last 3 months under consultant microbiologist recommendation - as per local policy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Hospital Filgotinib Jyseleca®) ICB Moderate to severe rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA676 – February 2021 Hospital Filgotinib () NHSE As per National Demand Management Plan Paediatric indications (where adult TA available) - NHSE policy specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Filgotinib Jyseleca® ICB moderately to severely active ulcerative colitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA792 – June 2022 Hospital Filgrastim (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan ▇▇▇▇▇ Syndrome - specialist centres only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human normal immunoglobulin Filgrastim (Gammagard®) (Gammagard®Various ▼) NHSE As Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Atidarsagene autotemcel Libmeldy NHSE metachromatic leukodystrophy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST18 - March 2022 ADVICE Atogepant Aquipta® ICB preventing migraine Specialist will initiate and provide the first 12 weeks of medication to the patient. TA973 – May 2024 SCA Atomoxetine (Strattera®) ICB Attention Deficit Hyperactivity Disorder in Adults for new treatment of symptoms that can be confirmed from childhood Shared Care Agreement Level 1 - Prescribe the drug and perform a higher level of monitoring, e.g. 6-monthly NG87 - Mar 18 SCA Atomoxetine (currently under review) (Strattera® ▼) ICB Attention Deficit Hyperactivity Disorder in Children & Adolescents Shared Care Agreement Level 3 - Prescribe the drug and perform significant monitoring including measurements such as height, weight, blood pressure and ECG NG87 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight ADVICE Atypical antipsychotics (LMWHexcept clozapine) (VariousVarious (except Clozaril® (Red)) ICB DVT Psychosis and schizophrenia in adults - As per NICE CG 178 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of one month. CG82 - Mar 09 GREEN Auto inflation device (if suspected out Otovent) (Otovent®) ICB Considered use for equalisation of hours - first dose onlypressure in the middle ear: in otitis media with effusion (glue ear) in children who are able to cooperate with treatment. Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin RED Autologous anti-CD19- transduced CD3+ cells Tecartus® NHSE Relapsed or refractory mantle cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA677 – February 2021 RED Autologous chondrocyte implantation (Spherox®) NHSE For treating symptomatic articular cartilage defects of the knee - Low Molecular Weight as per NICE TA 508 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA508 - Mar 18 RED Autologous serum eye drops (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI NHSE Dry eye Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, NutropinRED Avacopan Tavneos® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Anca-positive vasculitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) RED Avacopan Tavneos® NHSE HIV infection / post exposure prophylaxis (PEP) severe active granulomatosis with polyangiitis or microscopic polyangiitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. TA825 – September 20 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor RED Avalglucosidas e alfa AVAL® NHSE Emphysema Pompe disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA821 – August 2022 BLACK Human alpha1- proteinase inhibitor NAvanafil ▼ (Spedra® ▼) ICB Use of regular, daily doses for penile rehabilitation in prostate cancer/A emphysema post radical prostatectomy Not commissioned. No NHS prescribing in primary or secondary care TA965 NICE has not issued any guidance. BLACK Avapritinib N/A NHSE unresectable or metastatic gastrointestinal stromal tumours (terminated) Not commissioned. No NHS prescribing in primary or secondary care TA730 – March 2024 Hospital Human heterologous liver cells September 2021 RED Avatrombopag (HHLivC) (HeparescDoptelet®) NHSE Urea cycle disorders ICB treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan TA626 - NHSE policy Jun 2020 RED Avatrombopag Doptelet® ICB primary chronic immune thrombocytopenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin TA853 – December 2022 RED Avelumab (Flebogamma®) (FlebogammaBavencio®) NHSE As Metastatic ▇▇▇▇▇▇ cell carcinoma - as per National Demand Management Plan NICE TA 517 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin TA517 - Apr 18 RED Avelumab (Gammagard®) (GammagardBavencio®) NHSE As per National Demand Management Plan - NHSE policy axitinib for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) TA645 – September 2020 RED Avelumab Bavencio® NHSE As per National Demand Management Plan - NHSE policy untreated metastatic ▇▇▇▇▇▇ cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) TA691 – April 2021 RED Avelumab Bavencio® NHSE As per National Demand Management Plan - NHSE policy maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use TA788 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.May 2022

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Arimoclomol NHSE ▇▇▇▇▇▇▇ Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin ADVICE Aripiprazole (Abilify®) ICB Moderate to severe manic episodes in adolescents with bipolar I disorder - Low Molecular Weight as per NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (LMWHAbilify®) ICB Schizophrenia and bipolar mood disorder - as per NICE CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any unlicensed thyroid products (currently under reviewArmour Thyroid) ICB Any indication Not commissioned. No NHS prescribing in primary or secondary care RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various) (Various) ICB For patients requiring long term anticoagulation Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in whom warfarin is contraindicated post menopausal women - as per local protocol Formulary - Specialist advice required from primary or inappropriate Shared secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Hospital Arsenic trioxide (Trisenox®) NHSE Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR- alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 Hospital Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Heparinised saline Aspirin (Saline (heparinised)) ICB Central venous catheter lock Primary prevention of CVD in adults T1 or T2 Diabetes - as per RMOC guidance NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin (Feb 2019) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE Viral Hepatitis (B&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort Hospital Atacicept (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Ataluren ▼ (VariousTranslarna® ▼) NHSE HIV infection / post exposure prophylaxis (PEP) Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people aged ≥5 years who can walk - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy HST22 - Feb 2023 Hospital Atazanavir (VariousReyataz®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence NHSE HIV infection in combination with other antiretroviral drugs - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Atazanavir and Cobicistat (Aragam®) (AragamEvotaz®) NHSE As HIV infection in combination with other antiretroviral drugs - as per National Demand Management Plan - NHSE policy BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Atezolizumab (Flebogamma®) (FlebogammaTecentriq®) NHSE As Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per National Demand Management Plan NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan TA520 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.May 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. SCA Anagrelide ▼ (Xagrid® ▼ / Agrelin® / Agrylin®) ICB Thrombocythaemia Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Anakinra Kineret® NHSE Still’s disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA685 – March 2021 RED Anakinra (Kineret®) NHSE Cryopyrin-associated periodic syndrome (CAPS) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Adult onset Still's disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Rheumatoid arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NG100 - Oct 2020 RED Anakinra (Kineret®) NHSE Juvenile Idiopathic Arthritis (JIA) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Anakinra (Kineret®) NHSE Periodic fevers and autoinflammatory conditions Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Anastrozole (Arimidex®) ICB Breast cancer - as per NICE CG81 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 ADVICE Anastrozole (Arimidex®) ICB Post menopausal Women at moderate or High or moderate risk of breast Cancer unless they have severe osteoporosis Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG164 - updated Nov 2019 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Andexanet alfa Ondexxya® ICB for reversing anticoagulation from edoxaban Not commissioned. No NHS prescribing in primary or secondary care TA697 – May 2021 RED Andexanet alfa Ondexxya® ICB for reversing anticoagulation from apixaban or rivaroxaban Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA697 – May 2021 BLACK Angiotensin II Giapreza® ICB vasosuppressor-resistant hypotension caused by septic or distributive shock (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA859 – Jan 2023 Double Red Angiotensin-II receptor antagonists with ACE inhibitors (Various) ICB with ACE inhibitors (Not a licensed indication). Not recommended for routine use CG182 - Jul 14 RED Anidulafungin (Ecalta®) NHSE Fungal infection - invasive candidiasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Anifrolumab N/A NHSE active autoantibody-positive systemic lupus erythematosus (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA793 – June 2022 Double Red Antacids - various (Various) ICB Long term frequent use in functional dyspepsia - as per NICE CG 184 - Do Not Do Not recommended for routine use CG184 - Aug 04 Double Red Antibiotic prophylaxis (Various) ICB Infective endocarditis and interventional procedure (dental/non dental) - as per NICE CG 64 Not recommended for routine use CG64 - Jul 16 RED Antibiotics - intravenous / inhalation (Various) NHSE Cystic fibrosis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Double Red Antibiotics (LMWHoral for children) (Various) ICB DVT Fever in children without apparent source - as per NICE CG 160 - Do Not Do Not recommended for routine use NG143 - Nov 19 GREEN Anticoagulant monitoring self test strips (if suspected out of hours - first dose onlyVarious (e.g. CoaguChek)) ICB Anticoagulant self testing Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) RED Anti-D immunoglobuli n (Various) ICB Unstable angina/coronary artery disease/NSTEMI Routine anti-D prophylaxis (RAADP) - as per NICE TA 156 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin TA156 - Low Molecular Weight Aug 08 Double Red Antidepressant s (LMWH) (currently under reviewincluding SSRIs) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe (Routine use) for the drug and perform a more intense level treatment of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults alcohol misuse alone - as per RMOC guidance (Feb 2019) NICE CG 115 - Do Not Do Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort CG115 - Feb 11 RED Antihaemophili c Factor (Various, including St John's Wort) ICB All uses (Not a licensed indicationvon Willebrand Factor Complex). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy BCSH Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Bevacizumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (VariousAvastin®) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Bexarotene (VariousTargretin®) NHSE HIV infection / post exposure prophylaxis (PEP) All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy Double Red Bezafibrate (VariousBezalip; Fibrazate) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment Prevention of urinary incontinence CVD - as per NICE CG 171 - NICE 181 "Do Not Do Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Not a licensed indication). Zinplava®) ICB Prevention of recurrent clostridium difficile infection (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care CG171 TA601 - Nov 15 NF HRT implants Sep 19 Hospital Bictecravir (Variousin combination with emtricitabine and tenofivir alafenamide) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (HeparescBiktarvy ®) NHSE Urea cycle disorders HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Bimagrumab (Aragam®) (Aragam®BYM338)) NHSE As per National Demand Management Plan - NHSE policy Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Flebogamma®assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Binimetinib (FlebogammaMektovi®) NHSE As (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per National Demand Management Plan NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) Birch bark extract n/a NHSE As per National Demand Management Plan - NHSE policy epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. HST28 – September 2023 Hospital Human normal immunoglobulin Bivalirudin (GammanormAngiox®) (Gammanorm®) NHSE As ICB Treatment of ST-segment-elevation myocardial infarction - as per National Demand Management Plan - NHSE policy NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA230 - Jul 11 Hospital Human normal immunoglobulin Blinatumomab (Gammaplex®) (GammaplexBlincyto®) NHSE As per National Demand Management Plan - NHSE policy Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA686 – March 2021 Hospital Human normal immunoglobulin Blinatumomab ▼ (Gamunex®) (Gamunex®Blincyto® ▼) NHSE As Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults - as per National Demand Management Plan - NHSE policy NICE TA 450 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA450 - Jun 17 Hospital Human Normal Immunoglobulin Blisibimod (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Systemic lupus erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Double Red Clomethiazole (assume licensed unless statedHeminevrin®) Instructions PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for Prescriber NICE Guidance routine use CG115 - Feb 11 GREEN Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB DVT (if suspected out Prevention of hours - first dose only) atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. TA210 - Dec 10 Hospital Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB Unstable angina/coronary artery disease/NSTEMI Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin Double Red Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Clopidogrel (LMWHPlavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with low dose aspirin) (currently under reviewPlavix®, generics approved for use - Sept 2009) ICB Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (Variouswith aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of monitoring, e.g. quarterly in-patient stay. NICE has not issued any guidance. Double Red Heparinised saline ADVICE Clopidogrel (Saline with low dose aspirin) (heparinised)Plavix®, generics approved for use - Sept 2009) ICB Central venous catheter lock in adults - as per RMOC guidance ST-elevation myocardial infarction (Feb 2019STEMI) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 Formulary - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Hospital HIV vaccine Clozapine (HIV vaccineClozaril®, Denzapine®, Zaponex®) NHSE HIV infection prophylaxis ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. CG82 - Mar 09 Hospital HIV/AIDS treatments Cobicistat ▼ (VariousTybost® ▼) NHSE Use as a booster in treatment of HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence positive adults and adolescents - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 TA414 - Oct 16 Hospital Human heterologous liver cells Co-careldopa intestinal gel (HHLivC) (Heparesc®Duodopa® ▼) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As Severe ▇▇▇▇▇▇▇▇▇'▇ disease inadequately controlled by other preparations - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Cochlear implants (FlebogammaVarious) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (Flebogammaunlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE As per National Demand Management Plan of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Double Red Colestipol hydrochloride (GammagardColestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (GammagardNot a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE As Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. (Nebulised) Hospital Human normal immunoglobulin Colistimethate sodium Dry Powder Inhaler (Gammanorm®) (Gammanorm®Colobreathe® Dry Powder Inhaler) NHSE As Pseudomonas lung infection in cystic fibrosis - as per National Demand Management Plan - NHSE NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin TA276 - Mar 13 DM Collagenase clostridium histolyticum (GammaplexXiapex®) (Gammaplex®) NHSE As ICB Dupuytren's contracture with a palpable cord in adults - as per National Demand Management Plan NICE TA 459 Discontinued Medicines TA459 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Jul 17

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Hospital Bevacizumab (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (VariousAvastin®) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Radiation retinopathy macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Bexarotene (VariousTargretin®) NHSE HIV infection / post exposure prophylaxis (PEP) All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy Double Red Bezafibrate (VariousBezalip; Fibrazate) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment Prevention of urinary incontinence CVD - as per NICE CG 171 - NICE 181 "Do Not Do Do" Not recommended for routine use CG181 - Jul 14 BLACK Bezlotoxumab (Not a licensed indication). Zinplava®) ICB Prevention of recurrent clostridium difficile infection (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care CG171 TA601 - Nov 15 NF HRT implants Sep 19 Hospital Bictecravir (Variousin combination with emtricitabine and tenofivir alafenamide) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (HeparescBiktarvy ®) NHSE Urea cycle disorders HIV Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Bimagrumab (Aragam®) (Aragam®BYM338)) NHSE As per National Demand Management Plan - NHSE policy Inclusion body myositis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Bimekizumab Bimzelx® ICB active psoriatic arthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA916 – October 2023 Traffic Light Classification Drug Name Brand Name Commissione r Indication (Flebogamma®assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Bimekizumab Bimzelx® ICB axial spondyloarthritis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA918 – October 2023 Hospital Bimekizumab Bimzelx® ICB moderate to severe plaque psoriasis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA723 – September 2021 Hospital Binimetinib (FlebogammaMektovi®) NHSE As (with encorafenib (Braftovi®)) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults - as per National Demand Management Plan NICE TA 562 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA562 - Feb 19 BLACK Bioidentical HRT (Bioidentical hormone replacement therapy) ICB Menopausal symptoms Not commissioned. No NHS prescribing in primary or secondary care NG23 - Nov 13 Hospital Biotin (vitamin H) (Qizenday®, Cerenday®, MD1003) NHSE various Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) Birch bark extract n/a NHSE As per National Demand Management Plan - NHSE policy epidermolysis bullosa Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. HST28 – September 2023 Hospital Human normal immunoglobulin Bivalirudin (GammanormAngiox®) (Gammanorm®) NHSE As ICB Treatment of ST-segment-elevation myocardial infarction - as per National Demand Management Plan - NHSE policy NICE TA 230 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. TA230 - Jul 11 Hospital Human normal immunoglobulin Blinatumomab (Gammaplex®) (GammaplexBlincyto®) NHSE As per National Demand Management Plan - NHSE policy Acute lymphoblastic leukaemia in remission with minimal residual disease activity Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin TA589 - Jul 19 BLACK Blinatumomab N/A NHSE previously treated Philadelphia- chromosome-positive acute lymphoblastic leukaemia (Gamunex®terminated appraisal) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist serviceNot commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use TA686 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.March 2021

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Fluocinolone acetonide intravitreal implant (LMWH) (VariousIluvien®) ICB DVT Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 Hospital Fluocinolone acetonide intravitreal implant (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (VariousIluvien®) ICB Unstable angina/coronary artery disease/NSTEMI chronic diabetic macular oedema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA953 – March 2024 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight BLACK Folic acid (LMWH) (currently under review) (VariousGenerics are available) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level Secondary prevention of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults MI / reduce cardiovsacular risk post MI - as per RMOC guidance NICE CG 172 - Do Not Do (Feb 2019) Not recommended for routine use NICE has not issued any guidancea licensed indication). BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort CG172 - Nov 13 BLACK Folic Acid (Various, including St John's WortGenerics are available) ICB All uses For preventing hypertensive disorders during pregnancy - as per NICE CG 107 - Do Not Do (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. CG107 - Aug 10 Hospital HIV vaccine Fomepizole (HIV vaccineAntizol®) NHSE HIV infection prophylaxis ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Fondaparinux sodium (VariousArixtra®) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin CG94 - Mar 10 BLACK Fondaparinux sodium (Flebogamma®) (FlebogammaArixtra®) NHSE As Prophylaxis of venous thromboembolism in those undergoing major orthopaedic surgery of the legs - as per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist serviceNICE DoNotDo recommendation Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan NG89 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Mar 18

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Gevokizumab () NHSE Uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Gilteritinib Xospata® NHSE relapsed or refractory acute myeloid leukaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA642 – August 2020 Hospital Givosiran Givlaari NHSE Hepatic porphyria Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST16 - Nov 2021 BLACK Glasdegib () NHSE with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA646 – September 2020 Hospital Glatiramer (Copaxone®) NHSE Multiple Sclerosis - as per NICE TA 527 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA527 - Jun 18 Hospital Glecaprevir-pibrentasvir ▼ (Maviret® ▼) NHSE Chronic hepatitis C Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA499 - Jan 18 DM Glibenclamide (Various eg Daonil®, Euglucon®) ICB Type 2 diabetes mellitus Discontinued Medicines NICE has not issued any guidance. BLACK Gliclazide modified release (Diamicron® MR) ICB Type 2 diabetes mellitus Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Glofitamab Columvi® NHSE relapsed or refractory diffuse large B- cell lymphoma after 2 or more systemic treatments Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight TA927 – October 2023 Hospital Glucarpidase (LMWHVoraxase) (currently under review) (Various) ICB For NHSE Urgent treatment of methotrexate- induced renal dysfunction in patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults receiving high-dose MTX chemotherapy - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin BLACK Glucocorticoids (Flebogamma®inc hydrocortisone, prednisolone) (Flebogamma®Generics are available) ICB Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) - as per NICE CG 53 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG53 - Aug 07 BLACK Glucosamine (Various) ICB Osteoarthritis - as per NICE CG 177 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG177 - Feb 14 BLACK Glucosamine, Glucosamine & Chondroitin (Alateris and various) ICB Osteoarthritis Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. BLACK Gluten-free foods (Various) ICB Gluten sensitive enteropathies in all patients across N+W Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital Glycerol phenylbutyrate (Ravicti® 1.1 g/ml oral liquid) NHSE As per National Demand Management Plan Urea cycle disorders (specialist use only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin GlycoPEGylated Factor IX (Gammagard®) (GammagardRebinyn®) NHSE As per National Demand Management Plan - NHSE policy Haemophilia B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan ADVICE Glycopyrronium bromide Glycobromag ICB Hyperhidrosis Formulary - NHSE policy Restricted use – Prescribing Specialist advice required from primary or secondary care clinician with relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care initiation NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA29 - Sep 01 BLACK Fludarabine (Fludara®) NHSE B-cell Chronic Lymphocytic Leukaemia - 1st line treatment - as per NICE TA 119 Not commissioned. No NHS prescribing in primary or secondary care TA119 - Feb 07 ADVICE Fludroxycortide tape (previously Haelan) ICB Adjunctive therapy for chronic, localised, recalcitrant dermatoses that may respond to topical corticosteroids and particularly dry, scaling lesions Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidanceguidance BLACK Fludroxycortide tape (previously Haelan) ICB All unlicensed uses including hypertrophic scars and keloids Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight Hospital Fluocinolone acetonide intravitreal implant (LMWH) (VariousIluvien®) ICB DVT Treatment of chronic diabetic macular oedema after inadequate response to prior therapy - pseudophakic eye only - as per NICE TA 301 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA301 - Nov 13 Hospital Fluocinolone acetonide intravitreal implant (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (VariousIluvien®) ICB Unstable angina/coronary artery disease/NSTEMI Recurrent non-infectious uveitis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA590 - Jul 19 BLACK Fluocinolone acetonide intravitreal implant (Iluvien®) ICB Chronic diabetic macular oedema insufficiently responsive to available therapies in an eye with a natural lens (phakic eye) Not commissioned. No NHS prescribing in primary or secondary care TA613 - Nov 2019 Hospital Fluoride supplements - Toothpaste; dental products (Duraphat 0.619% DPF; 1.1% DPF Toothpaste) ICB Prevention of dental caries in at-risk patients (where the specialist is a dentist) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight BLACK Folic acid (LMWH) (currently under review) (VariousGenerics are available) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level Secondary prevention of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults MI / reduce cardiovsacular risk post MI - as per RMOC guidance NICE CG 172 - Do Not Do (Feb 2019) Not recommended for routine use NICE has not issued any guidancea licensed indication). BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort CG172 - Nov 13 BLACK Folic Acid (Various, including St John's WortGenerics are available) ICB All uses For preventing hypertensive disorders during pregnancy - as per NICE CG 107 - Do Not Do (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. CG107 - Aug 10 Hospital HIV vaccine Fomepizole (HIV vaccineAntizol®) NHSE HIV infection prophylaxis ICB Methanol and ethylene glycol poisoning (Poison Centre prescribing only) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Fondaparinux sodium (VariousArixtra®) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence unstable angina or non- ST segment elevation myocardial infarction (UA/NSTEMI) in adults for whom urgent (< 120 mins) invasive management i.e. percutaneous coronary intervention (PCI) is not indicated - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE regional network policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan CG94 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Mar 10

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Intratect®) (Intratect®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (IVIg) (Privigen®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Kiovig) (Kiovig®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Octagam) (Octagam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Subcuvia®) (Subcuvia®) NHSE As per National Demand Management Plan - NHSE Policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Subgam®) (Subgam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Vigam®) (Vigam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Vivaglobin®)) (Vivaglobin® (for s-c infusion) (discontinued 2011)) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA47 - Sep 02 Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Eptotermin alfa () NHSE Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) Erectile dysfunction drugs (Various) ICB DVT (if suspected out Erectile dysfunction - limited categories of hours - first dose only) patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) Erectile dysfunction drugs (Various) ICB Unstable angina/coronary artery disease/NSTEMI Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB BLUE Erenumab Aimovig® ICB Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA682 – March 2021 Hospital Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 2 Heparin - Low Molecular Weight or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (LMWHwhich may include an anthracycline or a taxane, and capecitabine) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance NICE TA 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Hospital Eribulin (Feb 2019Halaven®) Not recommended for routine NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins TA 515 Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort TA515 - Mar 18 BLACK Erlotinib (Various, including St John's WortTarceva®) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per East of NICE TA 227 and NHS England PAC policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE has not issued any guidance. Guidance Hospital HIV vaccine Erlotinib (HIV vaccineTarceva®) NHSE HIV infection prophylaxis First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Erythropoietin / Epoetin (VariousEprex®, NeoRecormon® and others) NHSE HIV infection / post exposure prophylaxis (PEP) Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy CG114 - Nov 11 Double Red Erythropoietin / Epoetin (VariousEprex®, NeoRecormon® and others) ICB Various (Anaemia in renal failure pre-dialysis. Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. recommended for routine use NG8 - Jun 15 BLACK Hormone Replacement Therapy (HRT) - systemic (Various) Esketamine Spravato® ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use TA854 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.December 2022

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A (Dysport®) ICB Muscle spasticity in neuromuscular conditions - cerebral palsy - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Botulinum Toxin Type A (Botox®, Dysport®) ICB Treatment of focal spasticity in Multiple Sclerosis or following stroke or brain injury - as per locally agreed policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight RED Botulinum Toxin Type A and B (LMWHBotox®) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber NHSE Intravesical use in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI spinal cord injury Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight RED Botulinum Toxin Type A and B (LMWHBotox®) (currently under review) (Various) ICB For patients requiring long term anticoagulation NHSE Focal spasticity in whom warfarin is contraindicated children Restricted use – Prescribing to remain with the hospital or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly specialist service. No prescribing in primary care NICE has not issued any guidance. Double Red Heparinised saline RED Brentuximab vedotin (Saline (heparinised)Adcetris®) ICB Central venous catheter lock NHSE CD30-positive Hodgkin lymphoma in adults with relapsed or refractory disease - as per RMOC guidance NICE TA 524 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA524 - Jun 18 RED Brentuximab vedotin (Feb 2019Adcetris®) NHSE Treating CD30-positive cutaneous T-cell lymphoma (CTCL) after at least 1 systemic therapy in adults, only if they have mycosis fungoides stage IIB or over, primary cutaneous anaplastic large cell lymphoma or Sézary syndrome - as per NICE TA 577 (NHSE comm Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA577 - Apr 19 BLACK Brentuximab vedotin (Adcetris®) NHSE Untreated advanced Hodgkin lymphoma (terminated appraisal) Not recommended commissioned. No NHS prescribing in primary or secondary care TA594 - Aug 19 RED Brentuximab vedotin (Adcetris®) NHSE in combination for routine untreated systemic anaplastic large cell lymphoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA641 – August 2020 RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE CD30-positive Hodgkin lymphoma - as per NICE TA 446 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA446 - Jun 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Brentuximab vedotin ▼ (Adcetris® ▼) NHSE For treating relapsed or refractory systemic anaplastic large cell lymphoma in adults, only if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 - as per NICE TA 478 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA478 - Oct 17 RED Brexucabtage ne autoleucel Tecartus® NHSE relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA893 – June 2023 RED Brigatinib (Alunbrig®) NHSE For treating ALK-positive advanced non-small-cell lung cancer in adults, after crizotinib - as per NICE TA 571 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA571 - Mar 19 RED Brigatinib Alunbrig® NHSE ALK-positive advanced non-small- cell lung cancer that has not been previously treated with an ALK inhibitor Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA670 – January 2021 RED Brimapitide NHSE Acute sensorineural hearing loss Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil Brimonidine tartrate gel (Mirvaso®) ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Treatment of facial erythema (rosacea) Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort RED Brincidofovir (Various, including St John's Wort(CMX001)) NHSE CMV infection Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. ADVICE Brivaracetam Briviact ICB epilepsy as alternative to levetiracetam Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Brodalumab (Kyntheum®) ICB All uses Moderate to severe plaque psoriasis - as per NICE TA 511 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA511 - Mar 18 RED Brolucizumab Beovu® ICB Wet age-related macular degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA672 – February 2021 BLUE Brolucizumab Beovu® ICB diabetic macular oedema NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA820 – August 2022 BLACK Bromocriptine () ICB Pharmacological neuroprotective therapy in ▇▇▇▇▇▇▇▇▇'▇ disease (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 BLACK HGH - SaizenBromocriptine mesilate (Parlodel®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per East NICE NG 17 Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 ADVICE Budenofalk (Budenofalk® ) ICB Crohn's disease in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. ADVICE Budenofalk (Budesonide 3mg caps & 9mg granules) (Budenofalk® ) ICB Collagenous colitis in adults Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Budesonide (oral viscous slurry) Pulmicort respules ICB eosinophilic oesophagitis in adults and paediatrics Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance BLACK Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults - treatment for maintenance of England PAC policy remission Not commissioned. No NHS prescribing in primary or secondary care TA708 – June 2021 ADVICE Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (GP may issue a SINGLE follow-up treatment (NOT for repeat) only if deemed necessary following assessment of response to initial treatment by given the hospital) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist responsible for the first script. TA708 – June 2021 RED Budesonide orodispersible tablets (Jorveza®) ICB Eosinophilic oesophagitis in adults (first treatment with follow-up assessment of effectiveness by the hospital) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA708 – June 2021 RED Bulevirtide Hepcludex® NHSE chronic hepatitis D Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA896 – June 2023 GREEN Buprenorphine (sublingual & oral lyophilisate) (Subutex® - generics available / Espranor®) NCC Opioid dependence (for use by prescribers with competence in treating opioid dependence) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. ADVICE Buprenorphine (transdermal) (Butec®, Transtec® patches) ICB Patients with renal impairment (eGFR 15-30, CKD 4) who have an accumulation of opiates and a resulting potential for toxicity Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLUE Buprenorphine Long-Acting Injection Buvidal®) ICB opioid substitution treatment NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required RMOC - April 2021 GREEN Bupropion (Zyban®) NCC Adjunct to smoking cessation Formulary - Drugs that can be initiated by Prescriber in Primary Care NG92 - Mar 18 BLACK Bupropion (Zyban®) ICB ADHD and other mental health conditions Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccineRED Burosumab Crysvita®) NHSE HIV infection X-linked hypophosphataemia in adults Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA993 – August 2024 RED Burosumab (Crysvita®) NHSE X-linked hypophosphataemia (XLH) with radiographic evidence of bone disease in children aged 1 year and over, and in young people with growing bones - as per NICE HST 8 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST8 - Oct 18 updated Sept 2024 Double Red Buspirone (Generics are available) ICB Augmentation of an antidepressant - as per NICE CG 90 - Do Not Do Not recommended for routine use CG90 - Oct 09 RED Busulfan (Myleran®) NHSE All indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Butyrophenon es (benperidol and haloperidol) (Various) ICB NICE Do Not Do - Use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED C1 Esterase Inhibitors NHSE Hereditary angioedema treatment and prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments BLACK Cabazitaxel (VariousJevtana®) NHSE Hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen - as per NICE TA 255 Not commissioned. No NHS prescribing in primary or secondary care TA255 - May 12 RED Cabazitaxel (Jevtana®) NHSE Metastatic hormone relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy - as per NICE TA 391 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA391 - Aug 16 BLACK Cabergoline (Cabaser®) ICB First-line use in ▇▇▇▇▇▇▇▇▇'▇ disease - as per NICE NG 71 (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 RED Cabotegravir Vocabria® NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy RED Cabotegravir Vocabria® NHSE with rilpivirine for treating HIV-1 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA757 – January 2022 RED Cabozantinib (VariousCometriq®) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence NHSE For treating medullary thyroid cancer - as per NICE CG 171 TA 516 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA516 - Mar 18 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Do Not Do Guidance RED Cabozantinib (Not a licensed indication)Cabometyx ®) NHSE Untreated advanced renal cell carcinoma in adults under defined circumstances - as per NICE TA 542 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA542 - Oct 18 RED Cabozantinib Cabometyx® NHSE previously treated advanced hepatocellular carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA849 – December 2022 BLACK Cabozantinib Cabometyx® NHSE previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine Not commissioned. No NHS prescribing in primary or secondary care CG171 TA928 – November 20 RED Cabozantinib Cabometyx® NHSE with nivolumab for untreated advanced renal cell carcinoma Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA964 – April 2024 RED Cabozantinib ▼ (Cabometyx ® ▼) NHSE Previously treated advanced renal cell carcinoma in adults after vascular endothelial growth factor (VEGF)-targeted therapy - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary as per NICE has not issued any guidanceTA 463 Restricted use – Prescribing to remain with the hospital or specialist service. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor No prescribing in primary care TA463 - Aug 17 RED Calcifidiol NHSE Emphysema Inborn errors in primary bile acid synthesis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Calcium and Ergocalciferol combi tablets (Generic tablets) ICB Prevention of osteoporosis-related fractures and falls Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells NICE has not issued any guidance. Double Red Calcium channel blockers - various (HHLivCVarious) ICB Treatment of cor pulmonale - as per NICE CG 101 - NICE Do Not Do Not recommended for routine use CG101 - Jul 10 Traffic Light Classification Drug Name Brand Name Commissioner Indication (Heparescassume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Canagliflozin ▼ (Invokana® ▼) ICB In combination therapy for treating type 2 diabetes - as per NICE TA 315 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA315 - Jun 14 ADVICE Canagliflozin ▼ (Invokana® ▼) ICB As a 4th monotherapy option for treating type 2 diabetes - as per NICE TA 390 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA390 - May 16 BLACK Canakinumab (Ilaris®) ICB Treatment of gouty arthritis attacks and reducing the frequency of subsequent attacks - as per NICE TA 281 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA281 - Apr 13 BLACK Canakinumab (Ilaris®) NHSE Urea cycle disorders Treatment of systemic juvenile idiopathic arthritis - - as per NHS England policy (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA302 - Nov 13 BLACK Cangrelor ▼ (Kengrexal® ▼) ICB Treatment for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti platelet therapy - as per NICE TA 351 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA351 - Jul 15 RED Cannabidiol Epidyolex® NHSE seizures caused by tuberous sclerosis complex Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin TA873 – March 2023 RED Cannabidiol with clobazam (Aragam®) (AragamEpidyolex®) NHSE As per National Demand Management Plan - NHSE policy Seizures associated with Dravet syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan TA614 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Dec 19

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (Humira® / Biosimilar) NHSE Children with Severe Refractory Uveitis with onset in childhood (age 2 or more up to 18 or less) - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (Humira® / Biosimilar) ICB Weekly use for treatment of psoriasis in adults Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE TA146 does not cover weekly use RED Adalimumab (biosimilar) (Imraldi® / Amjevita®) ICB Peripheral spondyloarthritis - following use of 3 DMARDs, as per local pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adalimumab (biosimilar) various ICB weekly use for dose escalations in NICE-approved rheumatology indications Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Adefovir Hepsera ® NHSE Hepatitis B Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG165 - Oct 17 Double Red ADHD drugs - various (Various) ICB First-line use in children and adolescents with ADHD - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Double Red ADHD drugs - various (Various) ICB Use in pre-school children - as per NICE CG 72 - Do Not Do (Not a licensed indication). Not recommended for routine use - Specialist initiation only CG72 - Feb 16 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Afamelanotide Scenesse® NHSE erythropoietic protoporphyria Not commissioned. No NHS prescribing in primary or secondary care HST27 – July 2023 RED Afatinib ▼ (Giotrif® ▼) NHSE Treatment of epidermal growth factor receptor mutation-positive locally advanced or metastatic non- small-cell lung cancer - as per NICE TA 310 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA310 - April 2014 BLACK Afatinib ▼ (Giotrif® ▼) NHSE Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy - as per NICE TA 444 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA444 - May 17 RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Wet Age-related Macular Degeneration (AMD) in new patients Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA294 - Jul 13 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema secondary to central retinal vein occlusion (CRVO) - as per NICE TA 305 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA305 - Feb 14 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Aflibercept (Zaltrap®) NHSE Treatment of metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (along with irinotecan and fluorouracil-based therapy) - as per NICE TA 307 - NICE Do Not Do Not commissioned. No NHS prescribing in primary or secondary care TA307 - Mar 14 RED Aflibercept (Eylea®) ICB Treatment of visual impairment caused by diabetic macular oedema (DMO) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA346 - Jul 15 RED Aflibercept (Eylea®) ICB Visual impairment caused by macular oedema after branch retinal vein occlusion - as per NICE TA 409 and local treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA409 - Sep 16 RED Aflibercept (Eylea®) ICB Treatment of visual impairment due to myopic choroidal neovascularisation in adults - as per NICE TA 486 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA486 - Nov 17 RED Aflibercept (Eylea®) ICB Treatment of Diabetic Macular Oedema (DMO) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Aflibercept (Eylea®) ICB Treatment of Wet Age-related Macular Degeneration (AMD) as part of a treat and extend regimen in line with the locally commissioned treatment pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight RED Aflibercept (LMWHswitched to Ranibizumab (Lucentis®) (VariousEylea®) ICB DVT Switching between products in the treatment of Wet Age-related Macular Degeneration (if suspected out of hours AMD) in previously treated patients who have not responded adequately to, or who have intolerance to aflibercept (Eylea®) - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI as per locally commissioned pathway Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin NG82 - Low Molecular Weight Jan 18 RED Agalsidase alfa and beta (LMWHReplagal® (alpha) / Fabrazyme® (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinisedbeta)) ICB Central venous catheter lock in adults - as per RMOC guidance NHSE Fabry disease (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEPα-galactosidase A deficiency) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy BLACK Agomelatine (VariousValdoxan®) ICB Various 4th line use in depression where other treatments have failed or not been tolerated (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRTterminated appraisal) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 TA231 - Nov 15 NF HRT implants Sep 11 RED Albumin bound paclitaxel Abraxane ® NHSE with gemcitabine for untreated metastatic pancreatic cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA476 - Sep 17 RED Albutrenpenon acog alfa (VariousIdelvion) ICB Hormone replacement therapy Non-formulary NHSE Haemophilia B - as per NHS England policy SSC1652 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. DM Albutropin NHSE Adult onset growth hormone deficiency . Discontinued Medicines NICE has not issued any guidance. RED Aldesleukin (Proleukin) NHSE Cancer - metastatic renal cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alectinib (Alecensa®) NHSE Untreated ALK-positive advanced non-small-cell lung cancer - as per NICE TA 536 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA536 - Aug 18 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor BLACK Alectinib ▼ (Alecensa® ▼) NHSE Emphysema Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - as per NICE TA 438 (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA438 - Mar 17 RED Alemtuzumab (Lemtrada®) NHSE Chronic lymphocytic leukaemia (CLL) - as per NHS England policy 2013 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (Lemtrada®) NHSE Pre-transplant immunosuppression Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab (MabCampat h®) NHSE Behcet's syndrome Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Alemtuzumab ▼ (Lemtrada® ▼) NHSE Treatment of adults with relapsing- remitting multiple sclerosis (RRMS) - as per NICE TA 312 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA312 – May 2014, updated May 2024 Double Red Alendronate / Vitamin D3 combination (Fosavance® ) ICB Treatment of post menopausal osteoporosis in women at risk of vitamin D deficiency Not recommended for routine use NICE has not issued any guidance. GREEN Alendronic acid (sodium alendronate) (Generics available) ICB Secondary prevention of osteoporotic fragility fractures in postmenopausal women - as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA161 - Oct 08 GREEN Alendronic acid (sodium alendronate) (Generic available) ICB Primary prevention of osteoporotic fragility fractures in postmenopausal women as per NICE criteria Formulary - Drugs that can be initiated by Prescriber in Primary Care TA464 - Aug 17 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Alfacalcidol (AlfaD®, One- Alpha®) ICB Preparation for hyperparathyroidectomy Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation NICE has not issued any guidance. RED Alglucosidase alfa (Myozyme®) NHSE Pompe disease (a lysosomal storage disorder caused by deficiency of acid alpha- glucosidase) - as per NHS England Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Alimemazine (Trimeprazine) (Generics) ICB Sedative in children / general antihistamine Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin RED Alipogene tiparvovec (Aragam®) (AragamGlybera®) NHSE As (Gene therapy treatment for ) Lipoprotein lipase deficiency - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin RED Alirocumab ▼ (Flebogamma®Praluent® ▼) (Flebogamma®) NHSE As ICB Treating primary hypercholesterolaemia and mixed dyslipidaemia - as per National Demand Management Plan NICE TA 393 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA393 - Jun 16 BLACK Aliskiren ▼ (Rasilez® ▼) ICB Treatment of essential hypertension - as per NICE CG 127 Not commissioned. No NHS prescribing in primary or secondary care CG127 - Sep 11 Double Red Alisporivir ((aka Debio 025 / DEB025 / UNIL-025)) NHSE Viral Hepatitis C - as per NHSE policy Not recommended for routine use NICE has not issued any guidance. Hospital Human normal immunoglobulin RED Alitretinoin (GammagardToctino®) ICB Treatment of severe chronic hand eczema - as per NICE TA 177 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA177 - Aug 09 Traffic Light Classification Drug Name Brand Name Commissioner Indication (Gammagardassume licenced unless stated) Instructions for Prescriber NICE Guidance BLACK Alpelisib Piqray® NHSE with fulvestrant for treating hormone-receptor positive, HER2- negative, PIK3CA-positive advanced breast cancer (terminated appraisal) Not commissioned. No NHS prescribing in primary or secondary care TA652 – October 2020 RED Alpelisib Piqray® NHSE with fulvestrant for treating hormone receptor-positive, HER2- negative, PIK3CA-mutated advanced breast cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA816 – August 2022 Double Red Alpha blockers - various (Various) ICB Treatment of cor pulmonale - as per NICE CG 101 . Not recommended for routine use CG101 - Jul 10 RED Alpha- mannosidase - recombinant human (Lamazym®) NHSE As Alpha Mannosidase deficiency - as per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin GREEN Alprostadil cream (GammanormVitaros®) ICB Erectile dysfunction (Gammanormas per SLS conditions only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. RED Alteplase (Actilyse®) ICB Treatment of acute ischaemic stroke - as per NICE TA 264 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA264 - Sep 12 Double Red Amantadine Hydrochloride (Lysovir®) ICB Treatment and prophylaxis of influenza Not recommended for routine use TA168 - Feb 09 RED Ambrisentan (Volibris® ▼) NHSE As Pulmonary Arterial Hypertension - specialist centre only Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. RED Amifampridine (phosphate) ▼ (Firdapse® ▼) NHSE Treatment of myasthenias - ▇▇▇▇▇▇▇-▇▇▇▇▇ syndrome - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Traffic Light Classification Drug Name Brand Name Commissioner Indication (Gammaplex®assume licenced unless stated) Instructions for Prescriber NICE Guidance RED Amikacin - liposomal for inhalation (GammaplexArikace®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist serviceGram-negative bacterial infection in Cystic Fibrosis . No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication Double Red Clomethiazole (assume licensed unless statedHeminevrin®) Instructions PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for Prescriber NICE Guidance routine use CG115 - Feb 11 GREEN Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB DVT (if suspected out Prevention of hours - first dose only) atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. TA210 - Dec 10 Hospital Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB Unstable angina/coronary artery disease/NSTEMI Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin Double Red Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (currently under review) (VariousSept 2009) ICB For patients requiring long term anticoagulation Primary prevention of CVD in whom warfarin is contraindicated T1 or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults T2 Diabetes - as per RMOC guidance (Feb 2019) NG17 and NG 28 Do Not Do's Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%NG17 - May 17 Double Red Clopidogrel (Plavix®, Bruiseze 0.8%generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, Lasonil generics approved for use - Sept 2009) ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (with aspirin) Formulary - Specialist advice required from primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available clinician with relevant expertise prior to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceinitiation Consultant responsible for the first script. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) TA80 - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Jul 04 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in-patient stay. NICE has not issued any guidance. ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB ST-elevation myocardial infarction (STEMI) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of in patient stay; max one month. NICE has not issued any guidance. Hospital Human alpha-1 proteinase inhibitor Clozapine (Clozaril®, Denzapine®, Zaponex®) ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG82 - Mar 09 Hospital Cobicistat ▼ (Tybost® ▼) NHSE Emphysema Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 TA414 - Oct 16 Hospital Human heterologous liver cells Co-careldopa intestinal gel (HHLivC) (Heparesc®Duodopa® ▼) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As Severe ▇▇▇▇▇▇▇▇▇'▇ disease inadequately controlled by other preparations - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Cochlear implants (FlebogammaVarious) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (Flebogammaunlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE As per National Demand Management Plan of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Double Red Colestipol hydrochloride (GammagardColestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (GammagardNot a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE As Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Human normal immunoglobulin Colistimethate sodium Dry Powder Inhaler (Gammanorm®) (Gammanorm®Colobreathe® Dry Powder Inhaler) NHSE As Pseudomonas lung infection in cystic fibrosis - as per National Demand Management Plan - NHSE NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 DM Collagenase clostridium histolyticum (Xiapex®) ICB Dupuytren's contracture with a palpable cord in adults - as per NICE TA 459 Discontinued Medicines TA459 - Jul 17 DM Collagenase Clostridium Histolyticum (Xiapex®) ICB Peyronie’s Disease Discontinued Medicines NICE has not issued any guidance. Hospital Human normal immunoglobulin BLACK Combination analgesics with caffeine (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist serviceICB Pain relief Not commissioned. No NHS prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary secondary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI RED Arimoclomol NHSE ▇▇▇▇▇▇▇ Pick disease Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin - Low Molecular Weight ADVICE Aripiprazole (LMWH) (currently under review) (VariousAbilify®) ICB For patients requiring long term anticoagulation Moderate to severe manic episodes in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults adolescents with bipolar I disorder - as per RMOC guidance NICE TA 292 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA292 - Jul 13 ADVICE Aripiprazole (Feb 2019Abilify®) Not recommended for routine use ICB Schizophrenia and bipolar mood disorder - as per NICE has not issued CG 82 and TA 213 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG82 - Mar 09 BLACK Armour Thyroid / any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil unlicensed thyroid products (Armour Thyroid) ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Any indication Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort RMOC guidance - June 2019 ADVICE Aromatase inhibitors (Various, including St John's Wort) (Various) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) Adjuvant hormonal treatment of early oestrogen-receptor-positive breast cancer in post menopausal women - as per East of England PAC policy Not commissioned. No NHS prescribing in local protocol Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation CG81 - Nov 06 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE has not issued any guidance. Hospital HIV vaccine Guidance RED Arsenic trioxide (HIV vaccineTrisenox®) NHSE HIV infection prophylaxis Acute promyelocytic leukaemia (characterised by the presence of the t[15;17] translocation or the PML/RAR-alpha gene) in adults - as per NICE TA 526 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA526 - Jun 18 GREEN Artificial saliva or salivary stimulants (Xerotin Oral spray or other cost- effective product) ICB Xerostomia from any cause where simple measures alone have been ineffective Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital HIV/AIDS treatments RED Asciminib Scemblix® NHSE chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA813 – August 2022 RED Asfotase alfa Strensiq® NHSE paediatric-onset hypophosphatasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care HST23 – March 2023 Double Red Aspirin (Various) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Aspirin () ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 Double Red Asunaprevir (with Daclatasvir) () NHSE HIV infection / post exposure prophylaxis Viral Hepatitis (PEPB&C) and Respiratory Syncytial Virus Not recommended for routine use NICE has not issued any guidance. RED Atacicept () NHSE Systemic Lupus Erythematosus (SLE) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy RED Ataluren ▼ (VariousTranslarna® ▼) ICB Various (Not NHSE Duchenne muscular dystrophy with a licensed indication). Available to buy over nonsense mutation in the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence dystrophin gene in people aged ≥5 years who can walk - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissionedNHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No NHS prescribing in primary or secondary care CG171 HST22 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Feb 2023 Traffic Light Classification Drug Name Brand Name Commissione r Commissioner Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor RED Atazanavir (Reyataz®) NHSE Emphysema HIV infection in combination with other antiretroviral drugs - as per BHIVA Guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells RED Atazanavir and Cobicistat (HHLivC) (HeparescEvotaz®) NHSE Urea cycle disorders HIV infection in combination with other antiretroviral drugs - as per BHIVA guidelines Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin RED Atezolizumab (Aragam®) (AragamTecentriq®) NHSE As Locally advanced or metastatic non- small-cell lung cancer after chemotherapy - as per National Demand Management Plan - NHSE policy NICE TA 520 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin TA520 - May 18 RED Atezolizumab (Flebogamma®) (FlebogammaTecentriq®) NHSE As Locally advanced or metastatic urothelial carcinoma after platinum- containing chemotherapy - as per National Demand Management Plan NICE TA 525 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) TA525 - Jun 18 RED Atezolizumab Tecentriq® NHSE As per National Demand Management Plan - NHSE policy monotherapy for untreated advanced non-small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) TA705 – June 2021 RED Atezolizumab Tecentriq® NHSE As per National Demand Management Plan - NHSE policy untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceTA739 – October 2021 BLACK Atezolizumab TECENTRIQ® NHSE with carboplatin and nab-paclitaxel for untreated advanced non- squamous non-small-cell lung cancer as per TA618 (terminated appraisal) Not commissioned. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) No NHS prescribing in primary or secondary care TA618 - Jan 20 RED Atezolizumab Tecentriq® NHSE As per National Demand Management Plan - NHSE policy adjuvant treatment of resected non- small-cell lung cancer Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use TA823 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.October 2022

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) (Various) ICB DVT (if suspected out of hours - first dose only) Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) (Various) ICB Unstable angina/coronary artery disease/NSTEMI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance AMB 2 Heparin - Low Molecular Weight (LMWH) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance (Feb 2019) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Traffic Light Classification Drug Name Brand Name Commissioner Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®® ) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®® ) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Intratect®) (Intratect®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (IVIg) (Privigen®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA47 - Sep 02 Hospital Eptinezumab VYEPTI® ICB preventing migraine Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA871 – March 2023 Hospital Eptotermin alfa () NHSE Complex spinal surgery Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance GREEN Heparin - Low Molecular Weight (LMWH) Erectile dysfunction drugs (Various) ICB DVT (if suspected out Erectile dysfunction - limited categories of hours - first dose only) patients under SLS for certain drugs Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. Hospital Heparin - Low Molecular Weight (LMWH) Erectile dysfunction drugs (Various) ICB Unstable angina/coronary artery disease/NSTEMI Severe distress from erectile dysfunction seeking treatment on the NHS Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB BLUE Erenumab Aimovig® ICB Preventing migraine NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available. For all other treatments, formulary application and discussion will be required TA682 – March 2021 Hospital Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 2 Heparin - Low Molecular Weight or more chemotherapy regimens only when it has progressed after at least 2 chemotherapy regimens (LMWHwhich may include an anthracycline or a taxane, and capecitabine) (currently under review) (Various) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level of monitoring, e.g. quarterly NICE has not issued any guidance. Double Red Heparinised saline (Saline (heparinised)) ICB Central venous catheter lock in adults - as per RMOC guidance NICE TA 423 Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 Hospital Eribulin (Feb 2019Halaven®) Not recommended for routine NHSE Treatment of locally advanced or metastatic breast cancer - as per NICE TA 423 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA423 - Dec 16 BLACK Eribulin (Halaven®) NHSE Locally advanced or metastatic breast cancer after 1 chemotherapy regimen - as per NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins TA 515 Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort TA515 - Mar 18 BLACK Erlotinib (Various, including St John's WortTarceva®) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) NHSE Monotherapy for maintenance treatment of non-small-cell lung cancer - as per East of NICE TA 227 and NHS England PAC policy Not commissioned. No NHS prescribing in primary or secondary care TA227 - Jun 11 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE has not issued any guidance. Guidance Hospital HIV vaccine Erlotinib (HIV vaccineTarceva®) NHSE HIV infection prophylaxis First-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer - as per NICE TA 258 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA258 - Jun 12 BLACK Erlotinib (Tarceva®) NHSE Treatment of non-small-cell lung cancer (NSCLC) as per NICE TA 374 - as per NHS England policy Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 BLACK Erlotinib (Tarceva®) NHSE Treating locally advanced or metastatic NSCLC that doesn’t test positive for the EGFR TK mutation (as per NICE TA 374) (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care TA374 - Dec 15 ADVICE Ertugliflozin (Steglatro®) ICB As monotherapy or with metformin for treating type 2 diabetes - as per NICE TA 572 Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation TA572 - Mar 19 GREEN Ertugliflozin (Steglatro®) ICB With metformin and a depeptidyl peptidase-4 inhibitor for Type 2 diabetes Formulary - Drugs that can be initiated by Prescriber in Primary Care TA583 - Jun 19 Hospital Erythropoietin (epoetin / darbepoetin) (Various) ICB Treatment of anaemia in people with cancer having chemotherapy - as per NICE TA 323 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA323 - Nov 14 Hospital Erythropoietin / Epoetin (Eprex) ICB Treatment of transfusion-dependent anaemia in myelodysplasia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital HIV/AIDS treatments Erythropoietin / Epoetin (VariousEprex®, NeoRecormon® and others) NHSE HIV infection / post exposure prophylaxis (PEP) Dialysis-induced anaemia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy CG114 - Nov 11 Double Red Erythropoietin / Epoetin (VariousEprex®, NeoRecormon® and others) ICB Various (Anaemia in renal failure pre-dialysis. Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. recommended for routine use NG8 - Jun 15 BLACK Hormone Replacement Therapy (HRT) - systemic (Various) Esketamine Spravato® ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). nasal spray for treatment-resistant depression Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor NHSE Emphysema Restricted use TA854 – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 Hospital Human heterologous liver cells (HHLivC) (Heparesc®) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Flebogamma®) (Flebogamma®) NHSE As per National Demand Management Plan Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammagard®) (Gammagard®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammanorm®) (Gammanorm®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gammaplex®) (Gammaplex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.December 2022

Restricted Use. Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Double Red Clomethiazole (Heminevrin®) PHE Community-based assisted alcohol withdrawal - as per NICE CG 115 - Do Not Do Not recommended for routine use CG115 - Feb 11 GREEN Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB DVT (if suspected out Prevention of hours - first dose only) atherosclerotic events Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. TA210 - Dec 10 Hospital Heparin Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight (LMWH) (VariousSept 2009) ICB Unstable angina/coronary artery disease/NSTEMI Prophylaxis pre-elective PCI Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. AMB 2 Heparin Double Red Clopidogrel (Plavix®, generics approved for use - Low Molecular Weight Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG17 - May 17 Double Red Clopidogrel (LMWHPlavix®, generics approved for use - Sept 2009) ICB Primary prevention of CVD in T1 or T2 Diabetes - as per NG17 and NG 28 Do Not Do's Not recommended for routine use NG28 - May 17 ADVICE Clopidogrel (with low dose aspirin) (currently under reviewPlavix®, generics approved for use - Sept 2009) ICB Acute Coronary Syndrome without ST- segment elevation (NSTEMI) (Variouswith aspirin) Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant responsible for the first script. TA80 - Jul 04 ADVICE Clopidogrel (with low dose aspirin) (Plavix®, generics approved for use - Sept 2009) ICB For patients requiring long term anticoagulation in whom warfarin is contraindicated Post elective percutaneous coronary intervention (PCI) - bare metal stent (Not a licensed indication). Formulary - Specialist advice required from primary or inappropriate Shared Care Agreement Level 2 - Prescribe the drug and perform a more intense level secondary care clinician with relevant expertise prior to primary care initiation Consultant should prescribe for an initial period of monitoring, e.g. quarterly in-patient stay. NICE has not issued any guidance. Double Red Heparinised saline ADVICE Clopidogrel (Saline with low dose aspirin) (heparinised)Plavix®, generics approved for use - Sept 2009) ICB Central venous catheter lock in adults - as per RMOC guidance ST-elevation myocardial infarction (Feb 2019STEMI) Not recommended for routine use NICE has not issued any guidance. BLACK Heparinoid Cream / Gel Hirudoid 0.3%, Bruiseze 0.8%, Lasonil ICB Improving circulation in bruising, superficial thrombophlebitis, chilblains, varicose veins Not commissioned. No NHS prescribing in primary or secondary care NICE has not issued any guidance. OTC Herbal medicines / supplements incl St John's Wort (Various, including St John's Wort) ICB All uses (Not a licensed indication). Available to buy over the counter CG90 Formulary - Oct 09 BLACK HGH - Saizen®, Zomacton®, Nordiflex®, Nutropin® Aq (Saizen®, Zomacton®, Nordiflex®, Nutropin Aq) ICB Growth hormone deficiency (GHD) - as per East of England PAC policy Not commissioned. No NHS prescribing in Specialist advice required from primary or secondary care NICE has not issued any guidance. Hospital HIV vaccine (HIV vaccine) NHSE HIV infection prophylaxis Restricted use – Prescribing clinician with relevant expertise prior to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidanceinitiation Consultant should prescribe for an initial period of in patient stay; max one month. Hospital HIV/AIDS treatments (Various) NHSE HIV infection / post exposure prophylaxis (PEP) Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. OTC Homeopathy (Various) ICB Various (Not a licensed indication). Available to buy over the counter NICE has not issued any guidance. BLACK Hormone Replacement Therapy (HRT) - systemic (Various) ICB Treatment of urinary incontinence - as per NICE CG 171 - NICE Do Not Do (Not a licensed indication). Not commissioned. No NHS prescribing in primary or secondary care CG171 - Nov 15 NF HRT implants (Various) ICB Hormone replacement therapy Non-formulary NICE has not issued any guidance. Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licensed licenced unless stated) Instructions for Prescriber NICE Guidance Hospital Human alpha-1 proteinase inhibitor Clozapine (Clozaril®, Denzapine®, Zaponex®) ICB Schizophrenia Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care CG82 - Mar 09 Hospital Cobicistat ▼ (Tybost® ▼) NHSE Emphysema Use as a booster in treatment of HIV positive adults and adolescents - as per NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. BLACK Human alpha1- proteinase inhibitor N/A emphysema Cobimetinib ▼ (in combination with vemurafenib) (Cotellic® ▼) NHSE Unresectable or metastatic BRAF V600 mutation-positive melanoma - as per NICE TA 414 Not commissioned. No NHS prescribing in primary or secondary care TA965 – March 2024 TA414 - Oct 16 Hospital Human heterologous liver cells Co-careldopa intestinal gel (HHLivC) (Heparesc®Duodopa® ▼) NHSE Urea cycle disorders Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Aragam®) (Aragam®) NHSE As Severe ▇▇▇▇▇▇▇▇▇'▇ disease inadequately controlled by other preparations - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin Cochlear implants (FlebogammaVarious) NHSE For children and adults with severe to profound deafness - specialist commissioned use only as per NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA566 - Mar 19 Double Red Codeine linctus generic ICB Cough suppressant Not recommended for routine use NICE has not issued any guidance BLACK Co-enzyme Q10 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 17 BLACK Co-enzyme Q11 (Healthcrafts, Nature's Best, Lamb, Natrahealth etc) ICB All indications - as per NICE NG 71 & CG181 Do Not Do Not commissioned. No NHS prescribing in primary or secondary care NG71 -Sep 17 GREEN Colecalciferol (Vitamin D) (Licensed Vitamin D products) ICB Treatment of vitamin D deficiency in adults and children - as per local policies Formulary - Drugs that can be initiated by Prescriber in Primary Care NICE has not issued any guidance. BLACK Colecalciferol (Vitamin D) (Various) ICB To increase adherence to statin treatment - as per NICE CG 181 - Do Not Do Not commissioned. No NHS prescribing in primary or secondary care CG181 - Jul 14 Traffic Light Classification Drug Name Brand Name Commissione r Indication (assume licenced unless stated) Instructions for Prescriber NICE Guidance ADVICE Colesevelam HCl (Cholestagel®) ICB Third-line option for (Flebogammaunlicensed) use in bile salt malabsorption causing diarrhoea (for patients under the NNUH only) (Not a licensed indication). Formulary - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Consultant/Specialist should prescribe for an initial period of 8 weeks (for new patients). NICE has not issued any guidance. Double Red Colesevelam HCl ▼ (Cholestagel® ▼) ICB Hypercholesterolaemia - as per NICE CG 181 Do Not Do Not recommended for routine use CG181 - Jul 14 Double Red Colesevelam hydrochloride (Cholestagel®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do Not recommended for routine use CG181 - Jul 14 Hospital Colestilan () NHSE As per National Demand Management Plan of hyperphosphataemia in adults on renal dialysis Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin Double Red Colestipol hydrochloride (GammagardColestid®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (GammagardNot a licensed indication). Not recommended for routine use CG181 - Jul 14 Double Red Colestyramine (Questran®) ICB Prevention of CVD, alone or added to a statin - as per NICE CG 181 - Do Not Do (Not a licensed indication). Not recommended for routine use CG181 - Jul 14 Hospital Colistimethate sodium (nebulised) (Colomycin®, Promixin®) NHSE As Pseudomonas lung infection in Cystic Fibrosis (new patients from 1st April 2013) - as per National Demand Management Plan - NHSE NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care TA276 - Mar 13 AMB Colistimethate sodium (Nebulised) (Colomycin®, Promixin®) ICB Ps. aeurginosa infection in non-Cystic Fibrosis bronchiectasis Prescribe the drug and perform a basic level of monitoring, e.g. a standard annual review NICE has not issued any guidance. Hospital Human normal immunoglobulin Colistimethate sodium Dry Powder Inhaler (Gammanorm®) (Gammanorm®Colobreathe® Dry Powder Inhaler) NHSE As Pseudomonas lung infection in cystic fibrosis - as per National Demand Management Plan - NHSE NICE TA 276 and NHS England policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin TA276 - Mar 13 DM Collagenase clostridium histolyticum (GammaplexXiapex®) (Gammaplex®) NHSE As ICB Dupuytren's contracture with a palpable cord in adults - as per National Demand Management Plan NICE TA 459 Discontinued Medicines TA459 - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human normal immunoglobulin (Gamunex®) (Gamunex®) NHSE As per National Demand Management Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance. Hospital Human Normal Immunoglobulin (Hizentra) (Hizentra®) NHSE As per National Demand Management Plan - NHSE policy Plan - NHSE policy Restricted use – Prescribing to remain with the hospital or specialist service. No prescribing in primary care NICE has not issued any guidance.Jul 17